TILLETT1 and his associates have demonstrated that a catalytic agent, streptokinase, and an enzyme, streptodornase * could be successfully employed as an adjunct in the treatment of certain conditions in which the accumulation of clotted blood and pus creates a barrier to therapeusis. These substances, which are elaborated by certain strains of beta hemolytic streptococci, offer a new physiologic approach to a difficult problem.
Christensen and MacLeod2 feel that SK acts as a catalyst, causing the transformation of a zymogen of normal human blood, designated by them as plasminogen, into a proteolytic enzyme, plasmin. Plasmin is capable of digesting fibrinogen and lysing fibrin. There is some question, however, whether the activation of plasminogen by SK is one of catalysis. Ratnoff described this activation reaction as a stoichiometric one, complying with the law of mass reaction; i. e., plasmin activity is proportional to the product of the concentrations of both
PORTFOLIO AG. STREPTOKINASE-STREPTODORNASE (VARIDASE) IN TREATMENT OF CORNEAL ULCERS. AMA Arch Ophthalmol. 1954;52(4):557–563. doi:10.1001/archopht.1954.00920050559007
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: